Menu Laterale Completo
🇮🇹 ITA 🇬🇧 ENG
× 📱 DOWNLOAD APP OUR SERVICE

🛑CURIS INC. ACHIEVEMENTS IN 2021

🛑CURIS INC. ACHIEVEMENTS IN 2021

Day: 08 | Time: 11:31:34 Curis Inc. (CRIS), a biotechnology company developing new therapies to slow or prevent the progression of cancer and extend life, has several important clinical trial milestones scheduled for the end of this year. One of the key milestones for Curis is the completion of enrollment in its Phase 1 trial for CA-4948, an investigational drug targeting hematologic malignancies. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of CA-4948 in patients with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). The company expects to announce the trial's preliminary data in the coming months. Another significant milestone for Curis is the initiation of a Phase 1 trial for CA-327, a potential treatment for patients with advanced solid tumors. The trial will evaluate the safety, tolerability, and pharmacokinetics of CA-327 in patients with advanced or metastatic solid tumors that have failed standard therapy or for which no standard therapy exists. The company plans to enroll patients in this trial by the end of the year. Additionally, Curis is expecting the completion of the dose-escalation stage of its Phase 1 trial for CA-4948 in patients with non-Hodgkin lymphomas (NHL). The trial aims to determine the maximum tolerated dose and recommended Phase 2 dose of CA-4948 in patients with relapsed or refractory NHL. The company plans to initiate the Phase 2 expansion cohorts in the first half of 2022. Curis is also actively working on advancing its pipeline of other investigational drugs, including CA-170, CA-4948, and CA-327, targeting various cancers and immune diseases. The company's goal is to develop innovative therapies that can improve patient outcomes and provide new treatment options for those in need. In conclusion, Curis Inc. has several important clinical trial milestones expected to be achieved by the end of this year. These milestones represent significant progress in the development of new therapies for cancer and demonstrate the company's commitment to improving patient outcomes.